Breaking: BMO Capital Reaffirms $86.0 Target Price On Gilead Sciences (NASDAQ:GILD) Shares, Reaffirms Their Original “Hold” Rating

April 22, 2018 - By Adrian Erickson

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It fall, as 95 investors sold Gilead Sciences, Inc. shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported.

Symphony Asset Management Lc holds 0.15% or 21,097 shares in its portfolio. Bb&T Corp reported 0.32% stake. Tiger Mgmt Lc holds 0.43% or 38,511 shares. Capital Interest Ca accumulated 7,630 shares. Paradigm Lc has invested 0.16% in Gilead Sciences, Inc. (NASDAQ:GILD). Synovus has invested 0.12% in Gilead Sciences, Inc. (NASDAQ:GILD). The Massachusetts-based Panagora Asset Mngmt Incorporated has invested 0.28% in Gilead Sciences, Inc. (NASDAQ:GILD). Arcadia Inv Corporation Mi reported 1,100 shares. California-based Intersect Llc has invested 0.24% in Gilead Sciences, Inc. (NASDAQ:GILD). Johnson Invest Counsel Inc reported 27,640 shares stake. Telemus Capital Limited Liability Corporation owns 8,221 shares or 0.05% of their US portfolio. Portland Advsr Limited Liability Company holds 3,478 shares. Moreover, Lincoln National Corporation has 0.03% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Oarsman Cap Inc stated it has 1.05% in Gilead Sciences, Inc. (NASDAQ:GILD). Wg Shaheen And Assocs Dba Whitney And stated it has 40,867 shares.

Since January 2, 2018, it had 0 insider buys, and 18 sales for $39.95 million activity. The insider Cogan John Francis sold $437,067. On Monday, April 2 MARTIN JOHN C sold $3.66M worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 50,000 shares. Meyers James R sold $8.02M worth of stock. Shares for $4.68M were sold by WILSON GAYLE E. Washington Robin L sold $401,566 worth of stock or 5,000 shares.

Gilead Sciences (NASDAQ:GILD) Rating Reaffirmed

They currently have a $86.0 target price on Gilead Sciences (NASDAQ:GILD). The target price by BMO Capital would suggest a potential upside of 16.69 % from the company’s last price. This has been revealed to investors in a research note on Tuesday, 2 January.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It fall, as 95 investors sold Gilead Sciences, Inc. shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported.

Symphony Asset Management Lc holds 0.15% or 21,097 shares in its portfolio. Bb&T Corp reported 0.32% stake. Tiger Mgmt Lc holds 0.43% or 38,511 shares. Capital Interest Ca accumulated 7,630 shares. Paradigm Lc has invested 0.16% in Gilead Sciences, Inc. (NASDAQ:GILD). Synovus has invested 0.12% in Gilead Sciences, Inc. (NASDAQ:GILD). The Massachusetts-based Panagora Asset Mngmt Incorporated has invested 0.28% in Gilead Sciences, Inc. (NASDAQ:GILD). Arcadia Inv Corporation Mi reported 1,100 shares. California-based Intersect Llc has invested 0.24% in Gilead Sciences, Inc. (NASDAQ:GILD). Johnson Invest Counsel Inc reported 27,640 shares stake. Telemus Capital Limited Liability Corporation owns 8,221 shares or 0.05% of their US portfolio. Portland Advsr Limited Liability Company holds 3,478 shares. Moreover, Lincoln National Corporation has 0.03% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Oarsman Cap Inc stated it has 1.05% in Gilead Sciences, Inc. (NASDAQ:GILD). Wg Shaheen And Assocs Dba Whitney And stated it has 40,867 shares.

Since January 2, 2018, it had 0 insider buys, and 18 sales for $39.95 million activity. The insider Cogan John Francis sold $437,067. On Monday, April 2 MARTIN JOHN C sold $3.66M worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 50,000 shares. Meyers James R sold $8.02M worth of stock. Shares for $4.68M were sold by WILSON GAYLE E. Washington Robin L sold $401,566 worth of stock or 5,000 shares.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 15 analysts covering Gilead Sciences (NASDAQ:GILD), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Gilead Sciences has $103.0 highest and $77.0 lowest target. $90.08’s average target is 22.23% above currents $73.7 stock price. Gilead Sciences had 25 analyst reports since October 27, 2017 according to SRatingsIntel. The rating was maintained by Cowen & Co on Wednesday, February 7 with “Buy”. The stock has “Hold” rating by Oppenheimer on Thursday, December 21. Argus Research downgraded Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, November 13 to “Hold” rating. As per Wednesday, January 3, the company rating was maintained by Credit Suisse. The company was maintained on Wednesday, February 7 by Bank of America. The firm has “Hold” rating given on Tuesday, January 2 by BMO Capital Markets. The firm earned “Hold” rating on Friday, October 27 by Jefferies. The firm earned “Buy” rating on Monday, February 5 by Mizuho. The rating was downgraded by Credit Suisse on Wednesday, December 20 to “Neutral”. Leerink Swann maintained the stock with “Hold” rating in Thursday, February 22 report.

The stock decreased 0.99% or $0.74 during the last trading session, reaching $73.7. About 4.23 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 22, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1 after the close. They expect $1.59 earnings per share, down 27.73 % or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.07B for 11.59 P/E if the $1.59 EPS becomes a reality. After $1.60 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63 % negative EPS growth.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $96.09 billion. The companyÂ’s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 21 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: